Current SP stinks. All retail holders must be in the red. Still no major CR so maybe an increase in sales this quarter will lessen the blow when they do seek more funds. The longer they delay the CR the more confident I feel about sales revenue in the background. Biotech stocks are volatile and can turn on just one positive announcement so I am riding this out. IMO only.
